Novo Nordisk Launches First GLP-1 Weight Loss Pill at $149 Monthly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Newsfilter
- Weight Loss Innovation: Novo Nordisk's Wegovy oral medication officially launches in the U.S., marking a new chapter in obesity treatment and expected to provide new options for over 100 million Americans living with obesity.
- Price Advantage: The drug's cash price ranges from $149 to $299 per month, significantly lower than the approximately $1,000 monthly cost of injection drugs, which is anticipated to address longstanding affordability issues and enhance market acceptance.
- Market Potential: Analysts predict that oral medications could capture a 24% share, or around $22 billion, of the global weight loss drug market by 2030, with Novo Nordisk's launch giving it a competitive edge in the rapidly evolving GLP-1 space.
- Clinical Efficacy: In a phase three trial involving over 300 adults with obesity, the highest dose of the oral medication helped patients lose an average of 16.6% of their weight after 64 weeks, demonstrating its effectiveness and competitiveness in weight management treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.660
Low
42.00
Averages
54.67
High
70.00
Current: 36.660
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aspen Expects Canadian Approval for Ozempic Generic by September
- Market Entry Timeline: Aspen Pharmacare's CEO Stephen Saad indicated that the company expects to receive Canadian regulatory approval for its generic version of Ozempic between May and September, positioning it advantageously for market formation.
- First-Mover Advantage Strategy: With Ozempic's market exclusivity in Canada expiring in January, Aspen aims to leverage this opportunity to be the first to launch its GLP-1 version, thereby gaining a competitive edge in the market.
- Market Impact Assessment: Saad noted that obtaining registration in Canada would allow Aspen to use it as a reference for entering Latin American and Middle Eastern markets, addressing the needs of patients who cannot afford the high prices of branded drugs and expanding its market share.
- Financial Performance Highlights: Aspen's recently released interim financials for H2 2025 show an 11% normalized EBITDA growth on a 4% revenue increase, indicating that the company is preparing for new product launches while maintaining steady growth.
See More
Oversold Stocks Set for Potential Rebound in Global Markets
- Oversold Stock List: A search using the Benzinga Pro Scanner identified stocks with market caps over $2 billion and RSI below 30, with KraneShares CSI China Internet ETF (KWEB) showing an RSI of 18.32, indicating extreme oversold conditions that may lead to a rebound if risk appetite improves.
- JD.com Performance: JD.com has an RSI of 24.42, with shares around $25.21, down 1.68% on the day, reflecting the overall pressure on Chinese consumer and internet stocks, potentially providing short-term trading opportunities for investors.
- Broad Market Overselling: iShares China Large-Cap ETF (FXI) posts an RSI of 24.99, trading near $35.89, indicating that selling pressure has broadened from individual stocks to major Chinese benchmarks, which may influence investors' regional allocation decisions.
- Emerging Market Signals: iShares MSCI India ETF (INDA) shows an RSI of 29.75, trading around $50.03, indicating oversold conditions and suggesting that selling pressure has spread to broader Asian and emerging markets, potentially prompting long-term investors to reassess their risk tolerance.
See More
FDA Warns Novo Nordisk Over Misleading Ozempic Ad
- Regulatory Warning: The FDA issued a letter on February 26 warning Novo Nordisk (NVO) for making “false or misleading” claims in its Ozempic TV advertisement, marking the second instance of U.S. regulatory scrutiny within a month, highlighting increasing compliance risks in its GLP-1 product promotions.
- Advertisement Issues: The FDA noted that Novo Nordisk's ad, “There’s Only One Ozempic,” misrepresented the injectable’s approved uses and suggested, without sufficient evidence, that the drug was superior to other GLP-1s for Type 2 diabetes, potentially affecting patient medication choices.
- Immediate Action Required: The FDA called on Novo Nordisk to take immediate action to address any violations, including plans to cease airing the ad or potentially halt the distribution of Ozempic, indicating a strict regulatory stance that could directly impact the company's sales.
- Historical Warnings: Novo Nordisk received a similar warning from the FDA in early February regarding misleading claims in its advertisement for the newly launched oral weight loss therapy Wegovy, indicating ongoing regulatory challenges that may affect the company's market image and investor confidence.
See More
Stock Index Futures Rise Amid Middle East Developments
- CoreWeave Partnership: AI search firm Perplexity has signed a deal with cloud computing company CoreWeave to utilize its data centers for new AI services, resulting in a 5.80% premarket gain, aimed at diversifying its customer base and enhancing market competitiveness.
- Novo Nordisk Regulatory Warning: Despite the FDA warning Novo Nordisk for “false or misleading” claims in its Ozempic advertisement, the stock rose 3.14% in premarket trading, indicating market confidence in its long-term prospects.
- Meta AI Organization Formation: Meta's stock increased by 0.61% in premarket trading as it plans to establish a new applied AI engineering organization to bolster its superintelligence capabilities, partnering with its Superintelligence Lab to accelerate model optimization and enhance technological competitiveness.
- Dycom Strong Earnings: Dycom Industries saw a 6.1% rise in premarket trading after reporting record fiscal fourth-quarter results and projecting fiscal 2027 contract revenues of $6.85 billion to $7.15 billion, exceeding market expectations and reflecting strong growth and margin expansion potential.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Recovery: The NASDAQ 100 Pre-Market Indicator rose by 154.9 points to 24,874.98, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Overview: ProShares UltraPro QQQ (TQQQ) increased by 0.75 to $48.85 with a trading volume of 10,209,915 shares, representing a 179.14% rise from its 52-week low, showcasing strong market demand and investor confidence.
- Strong Bitcoin ETF Performance: iShares Bitcoin Trust ETF (IBIT) gained 1.78 to $40.48 with 10,151,308 shares traded, reflecting a 14.67% increase from its 52-week low, indicating signs of recovery in the cryptocurrency market.
- NIO Earnings Forecast: NIO Inc. (NIO) rose by 0.0492 to $4.64 with a trading volume of 888,382 shares, scheduled to report earnings on March 10, 2026, with a consensus EPS forecast of -0.05, representing a 47% increase over last year's EPS.
See More
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
- Technology Integration: Hoth Therapeutics announced the integration of OpenAI API into the HT-KIT development workflow to support IND-enabling development for rare and aggressive KIT-driven cancers, enhancing data analysis and molecular modeling efficiency.
- Preclinical Results: HT-KIT achieved over 80% reduction of KIT mRNA/protein in both in vitro and in vivo models, with no dose-limiting toxicities observed, demonstrating its potential in systemic mastocytosis and gastrointestinal stromal tumors.
- Tumor Reduction Effects: Statistically significant tumor volume reduction was observed by Day 8 in xenograft models, accompanied by apoptotic signaling consistent with KIT pathway knockdown, indicating substantial therapeutic efficacy.
- Regulatory Readiness: Hoth Therapeutics has completed GLP-validated bioanalytical methods to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, with HT-KIT advancing toward IND submission and Phase 1 clinical evaluation, having received Orphan Drug Designation.
See More
Aspen Expects Canadian Approval for Ozempic Generic by September
- Market Entry Timeline: Aspen Pharmacare's CEO Stephen Saad indicated that the company expects to receive Canadian regulatory approval for its generic version of Ozempic between May and September, positioning it advantageously for market formation.
- First-Mover Advantage Strategy: With Ozempic's market exclusivity in Canada expiring in January, Aspen aims to leverage this opportunity to be the first to launch its GLP-1 version, thereby gaining a competitive edge in the market.
- Market Impact Assessment: Saad noted that obtaining registration in Canada would allow Aspen to use it as a reference for entering Latin American and Middle Eastern markets, addressing the needs of patients who cannot afford the high prices of branded drugs and expanding its market share.
- Financial Performance Highlights: Aspen's recently released interim financials for H2 2025 show an 11% normalized EBITDA growth on a 4% revenue increase, indicating that the company is preparing for new product launches while maintaining steady growth.
See More
Oversold Stocks Set for Potential Rebound in Global Markets
- Oversold Stock List: A search using the Benzinga Pro Scanner identified stocks with market caps over $2 billion and RSI below 30, with KraneShares CSI China Internet ETF (KWEB) showing an RSI of 18.32, indicating extreme oversold conditions that may lead to a rebound if risk appetite improves.
- JD.com Performance: JD.com has an RSI of 24.42, with shares around $25.21, down 1.68% on the day, reflecting the overall pressure on Chinese consumer and internet stocks, potentially providing short-term trading opportunities for investors.
- Broad Market Overselling: iShares China Large-Cap ETF (FXI) posts an RSI of 24.99, trading near $35.89, indicating that selling pressure has broadened from individual stocks to major Chinese benchmarks, which may influence investors' regional allocation decisions.
- Emerging Market Signals: iShares MSCI India ETF (INDA) shows an RSI of 29.75, trading around $50.03, indicating oversold conditions and suggesting that selling pressure has spread to broader Asian and emerging markets, potentially prompting long-term investors to reassess their risk tolerance.
See More
FDA Warns Novo Nordisk Over Misleading Ozempic Ad
- Regulatory Warning: The FDA issued a letter on February 26 warning Novo Nordisk (NVO) for making “false or misleading” claims in its Ozempic TV advertisement, marking the second instance of U.S. regulatory scrutiny within a month, highlighting increasing compliance risks in its GLP-1 product promotions.
- Advertisement Issues: The FDA noted that Novo Nordisk's ad, “There’s Only One Ozempic,” misrepresented the injectable’s approved uses and suggested, without sufficient evidence, that the drug was superior to other GLP-1s for Type 2 diabetes, potentially affecting patient medication choices.
- Immediate Action Required: The FDA called on Novo Nordisk to take immediate action to address any violations, including plans to cease airing the ad or potentially halt the distribution of Ozempic, indicating a strict regulatory stance that could directly impact the company's sales.
- Historical Warnings: Novo Nordisk received a similar warning from the FDA in early February regarding misleading claims in its advertisement for the newly launched oral weight loss therapy Wegovy, indicating ongoing regulatory challenges that may affect the company's market image and investor confidence.
See More
Stock Index Futures Rise Amid Middle East Developments
- CoreWeave Partnership: AI search firm Perplexity has signed a deal with cloud computing company CoreWeave to utilize its data centers for new AI services, resulting in a 5.80% premarket gain, aimed at diversifying its customer base and enhancing market competitiveness.
- Novo Nordisk Regulatory Warning: Despite the FDA warning Novo Nordisk for “false or misleading” claims in its Ozempic advertisement, the stock rose 3.14% in premarket trading, indicating market confidence in its long-term prospects.
- Meta AI Organization Formation: Meta's stock increased by 0.61% in premarket trading as it plans to establish a new applied AI engineering organization to bolster its superintelligence capabilities, partnering with its Superintelligence Lab to accelerate model optimization and enhance technological competitiveness.
- Dycom Strong Earnings: Dycom Industries saw a 6.1% rise in premarket trading after reporting record fiscal fourth-quarter results and projecting fiscal 2027 contract revenues of $6.85 billion to $7.15 billion, exceeding market expectations and reflecting strong growth and margin expansion potential.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Recovery: The NASDAQ 100 Pre-Market Indicator rose by 154.9 points to 24,874.98, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Overview: ProShares UltraPro QQQ (TQQQ) increased by 0.75 to $48.85 with a trading volume of 10,209,915 shares, representing a 179.14% rise from its 52-week low, showcasing strong market demand and investor confidence.
- Strong Bitcoin ETF Performance: iShares Bitcoin Trust ETF (IBIT) gained 1.78 to $40.48 with 10,151,308 shares traded, reflecting a 14.67% increase from its 52-week low, indicating signs of recovery in the cryptocurrency market.
- NIO Earnings Forecast: NIO Inc. (NIO) rose by 0.0492 to $4.64 with a trading volume of 888,382 shares, scheduled to report earnings on March 10, 2026, with a consensus EPS forecast of -0.05, representing a 47% increase over last year's EPS.
See More
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
- Technology Integration: Hoth Therapeutics announced the integration of OpenAI API into the HT-KIT development workflow to support IND-enabling development for rare and aggressive KIT-driven cancers, enhancing data analysis and molecular modeling efficiency.
- Preclinical Results: HT-KIT achieved over 80% reduction of KIT mRNA/protein in both in vitro and in vivo models, with no dose-limiting toxicities observed, demonstrating its potential in systemic mastocytosis and gastrointestinal stromal tumors.
- Tumor Reduction Effects: Statistically significant tumor volume reduction was observed by Day 8 in xenograft models, accompanied by apoptotic signaling consistent with KIT pathway knockdown, indicating substantial therapeutic efficacy.
- Regulatory Readiness: Hoth Therapeutics has completed GLP-validated bioanalytical methods to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, with HT-KIT advancing toward IND submission and Phase 1 clinical evaluation, having received Orphan Drug Designation.
See More
